SANA BIOTECHNOLOGY INC (SANA)

US7995661045 - Common Stock

4.3  +2.65 (+160.61%)

After market: 4.41 +0.11 (+2.56%)

Fundamental Rating

2

Overall SANA gets a fundamental rating of 2 out of 10. We evaluated SANA against 561 industry peers in the Biotechnology industry. The financial health of SANA is average, but there are quite some concerns on its profitability. SANA does not seem to be growing, but still is valued expensively.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SANA has reported negative net income.
In the past year SANA has reported a negative cash flow from operations.
In the past 5 years SANA always reported negative net income.
SANA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -54.67%, SANA is in line with its industry, outperforming 44.14% of the companies in the same industry.
SANA has a Return On Equity (-104.56%) which is in line with its industry peers.
Industry RankSector Rank
ROA -54.67%
ROE -104.56%
ROIC N/A
ROA(3y)-38.13%
ROA(5y)-36.99%
ROE(3y)-67.12%
ROE(5y)-63.01%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SANA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for SANA has been increased compared to 1 year ago.
Compared to 5 years ago, SANA has more shares outstanding
SANA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -3.23, we must say that SANA is in the distress zone and has some risk of bankruptcy.
SANA has a Altman-Z score of -3.23. This is comparable to the rest of the industry: SANA outperforms 45.59% of its industry peers.
SANA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.23
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

SANA has a Current Ratio of 4.47. This indicates that SANA is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.47, SANA perfoms like the industry average, outperforming 50.09% of the companies in the same industry.
SANA has a Quick Ratio of 4.47. This indicates that SANA is financially healthy and has no problem in meeting its short term obligations.
SANA's Quick ratio of 4.47 is in line compared to the rest of the industry. SANA outperforms 51.71% of its industry peers.
Industry RankSector Rank
Current Ratio 4.47
Quick Ratio 4.47

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 1.45% over the past year.
EPS 1Y (TTM)1.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1350%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 10.05% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y12.08%
EPS Next 2Y16.95%
EPS Next 3Y10.05%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SANA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SANA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.95%
EPS Next 3Y10.05%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SANA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SANA BIOTECHNOLOGY INC

NASDAQ:SANA (1/8/2025, 8:27:27 PM)

After market: 4.41 +0.11 (+2.56%)

4.3

+2.65 (+160.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-08 2024-11-08/bmo
Earnings (Next)N/A N/A
Inst Owners90.41%
Inst Owner Change0%
Ins Owners8.62%
Ins Owner Change-1.34%
Market Cap960.06M
Analysts80
Price Target10.2 (137.21%)
Short Float %18.1%
Short Ratio20.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.8%
Min EPS beat(2)1.83%
Max EPS beat(2)27.76%
EPS beat(4)2
Avg EPS beat(4)-6.81%
Min EPS beat(4)-51.07%
Max EPS beat(4)27.76%
EPS beat(8)5
Avg EPS beat(8)9.36%
EPS beat(12)8
Avg EPS beat(12)9.4%
EPS beat(16)11
Avg EPS beat(16)-27.31%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.98%
PT rev (3m)-26.47%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.39%
EPS NY rev (1m)0%
EPS NY rev (3m)1.02%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.28
P/tB 10.36
EV/EBITDA N/A
EPS(TTM)-1.36
EYN/A
EPS(NY)-0.89
Fwd EYN/A
FCF(TTM)-1.23
FCFYN/A
OCF(TTM)-1.02
OCFYN/A
SpS0
BVpS1.31
TBVpS0.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.67%
ROE -104.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-38.13%
ROA(5y)-36.99%
ROE(3y)-67.12%
ROE(5y)-63.01%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 204.82%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.47
Quick Ratio 4.47
Altman-Z -3.23
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)161.63%
Cap/Depr(5y)463.09%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1350%
EPS Next Y12.08%
EPS Next 2Y16.95%
EPS Next 3Y10.05%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-9.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12.72%
EBIT Next 3Y7.38%
EBIT Next 5YN/A
FCF growth 1Y20.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.66%
OCF growth 3YN/A
OCF growth 5YN/A